Newest
-
What will be the future of laser coding machines?
-
The 2nd Tomato Culture Festival of China's High-quality Tomato Town in 2024 was officially launched
-
2024 Shanghai Summer Ends - STORM Music Festival and Rolex Shanghai Masters in October
-
OutSystems Celebrates the World's Leading Software Innovators at the 2024 Innovation Awards and Build for the Future Hackathon
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-27 I-Mab Biopharma HaiPress
ROCKVILLE,Md.,Aug. 26,2024 -- I-Mab (NASDAQ: IMAB),a US-based,global,clinical-stage biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10,2024.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Time
Tuesday,September 10at5:00 PM ET
Presenters
Sean Fu,PhD,Interim Chief Executive Officer (CEO)
Phillip Dennis,MD,Chief Medical Officer (CMO)
Webcast link
Here
Meetings
One-on-one and small group meetings:September 9 – 10,2024
Management
Participants
Sean Fu,Interim CEO
Joe Skelton,Chief Financial Officer (CFO)
Phillip Dennis,CMO
Tyler Ehler,Senior Director,Investor Relations
The webcast will also be available under "Event Calendar" onI-Mab'sIR website
athttps://ir.i-mabbiopharma.com/
For more information,please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland. For more information,please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com